Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange Detected- Added a government funding notice about potential delays and current operating status, plus a link to cc.nih.gov and opm.gov for updates. - Bumped version from v3.1.0 to v3.2.0.SummaryDifference11%

- Check30 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or update a v3.1.0 release has superseded v3.0.2.SummaryDifference0.3%

- Check44 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.6%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.6%

- Check58 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.SummaryDifference29%

- Check73 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.